Living with Crohn's: A Personal Account
ABSTRACT: The lifelong, chronic nature of Crohn's disease produces incessant stress that affects individuals physically, emotionally, and socially. Coping with the symptoms and treatment is improved when persons engage their faith and spiritual resources. Clear understanding of the physical and emotional aspects of Crohn's can support a person's ability to manage the disease. Knowledge of emerging treatments also provides nurses with hopeful input to share with their patients.
This study analyzed the long-term incidence of malignancy with vedolizumab, a gut-selective antibody approved to treat moderate-to-severe Crohn's disease and ulcerative colitis in adults.Alimentary Pharmacology &Therapeutics
ConclusionOur work demonstrated that WMW can prevent intestinal fibrosis and the mechanisms involved may be related to the inhibition of colon fibroblasts activation.Graphical abstract
Authors: Motoi Y, Ito Z, Suzuki S, Takami S, Matsuo K, Sato M, Ota Y, Tsuruta M, Kojima M, Noguchi M, Uchiyama K, Kubota T Abstract Crohn's disease (CD) development is thought to involve genetic factors related to immune response as well as environmental factors, such as intestinal bacteria and diet, though no clear cause has yet been identified. In our previous study, we found that the concentrations of linoleic acid, stearic acid, and metabolites in erythrocytes differed between CD patients and healthy subjects. These factors related to lipid metabolism are controlled by Δ6 desaturase (fatty acid desaturase...
CONCLUSIONS: Testing for S100B and calprotectin could be a useful screening tool to better predict IBD activity. PMID: 31957846 [PubMed - in process]
Advances in anti-TNF drugs will be in the spotlight at the upcoming Crohn's and Colitis Congress. One expert believes a cure will come in the lifetime of some of the children he currently treats.Medscape Medical News
Publication date: Available online 20 January 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Shan-Han Chang, Hsin-Yun Sun, Chia-Tung Shun, Shu-Chen Wei
Conclusion and Relevance: In our meta-analysis, obesity was associated with the inferior response of anti-TNF treatments in UC patients. Clinicians should be aware that obese UC patients may require higher doses in anti-TNF treatment. PMID: 31955605 [PubMed - as supplied by publisher]
Condition: Crohn's Disease Intervention: Drug: Mirikizumab Sponsor: Eli Lilly and Company Not yet recruiting
Condition: Crohn Disease Intervention: Other: No intervention Sponsor: Janssen-Cilag Ltd. Not yet recruiting
Condition: Crohn Disease Interventions: Dietary Supplement: Modulen; Drug: Budesonide Sponsor: Hillel Yaffe Medical Center Not yet recruiting